Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | CASR | P41180 | 2/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557453 | 0.87 | HDAC8 (0.45) | HDAC8HTR1AHTR7KDM4EALDH1A1 | |
| SCHEMBL557506 | 0.86 | HDAC8 (0.39) | HDAC8HTR1AHTR7CASRP2RY12 | |
| SCHEMBL1897841 | 0.82 | HDAC8 (0.43) | HDAC8HTR1AHTR7KDM4EALDH1A1 | |
| SCHEMBL2531573 | 0.79 | HDAC1 (0.35) | HDAC1HDAC2HDAC6 | |
| SCHEMBL558113 | 0.78 | HDAC1 (0.38) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL557859 | 0.78 | HDAC1 (0.38) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL557865 | 0.78 | HDAC1 (0.38) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL557472 | 0.78 | HDAC1 (0.38) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL557648 | 0.77 | SLC7A5 (0.35) | HDAC8CASRHDAC1 | |
| SCHEMBL1744910 | 0.76 | HDAC8 (0.51) | HDAC8HTR1AHTR7ALDH1A1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| EP-2256130-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-09-25 | — | — | EP | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| EP-1846446-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-06-26 | — | — | EP | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| EP-1846446-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035104-A1 | Insulin derivatives | IAPP, INSR, GPR119 | HDAC8 1374/4885HTR1A 3864/4885HTR7 2753/4885 |
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | HDAC8 1287/4885HTR1A 4178/4885HTR7 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.